期刊文献+

结直肠癌组织Survivin和VEGF表达与临床病理特征相关性的研究 被引量:4

Relationship between expressions of Survivin and VEGF in colorectal carcinoma and their clinicopathologic features
下载PDF
导出
摘要 目的:探讨结直肠癌组织中凋亡抑制基因Survivin和血管内皮生长因子(vascular endothelial growth factor,VEGF)表达与结直肠癌临床病理特征的相关性,及其在结直肠癌发生发展中的作用。方法:应用免疫组织化学方法检测61例结直肠癌及肿瘤切端非癌组织中VEGF及Survivin的表达。结果:Survivin在正常结直肠组织不表达,结直肠癌组织中45例(73.77%)阳性表达,VEGF在非癌结直肠组织不表达,癌组织中42例(68.85%)阳性表达。结直肠癌组织中Survivin及VEGF表达与肿瘤浸润深度、Duke分期及有无淋巴结转移关系密切,P<0.05。结论:Survivin和VEGF参与结直肠癌血管新生的调节,与肿瘤的发生发展及预后有密切关系。 OBJECTIVE: To explore the relationship between the expressions of apoptosis suppression gene Survivin and vascular endothelial growth factor(VEGF) in colorectal carcinoma and their clinicopathologic features,and their role in the development and progression of colorectal carcinoma.METHODES: The expressions of Survivin and VEGF were assayed by immunohistochemical staining(SP) in 61 cases of colorectal carcinoma and their non-carcinomatous ends of cut specimens.RESULTS: The normal colorectal tissues were negative for Survivin,but the positive expression in 45 cases(73.77%) of colorectal carcinoma tissues.The expression of VEGF in 42 cases(68.85%) of colorectal carcinoma was positive,but no expression in normal colorectal tissues.The expressions of Survivin and VEGF in colorectal carcinoma were correlated closely with the extent of tumor invasive,Duke stages and lymph node metastasis,P〈0.05.CONCLUSION: Survivin and VEGF are involved in the regulation of angiogenesis in colorectal carcinoma,and correlated closely with the development,progression and prognosis of colorectal carcinoma.
出处 《中华肿瘤防治杂志》 CAS 2008年第18期1390-1392,共3页 Chinese Journal of Cancer Prevention and Treatment
关键词 结直肠肿瘤 血管生成 血管内皮生长因子 生存素 免疫组织化学 colorectal neoplasms angiogenesis vascular endothelial growth factor Survivin immunohistochemistry
  • 相关文献

参考文献14

  • 1李连弟,饶克勤,张思维,鲁凤珠,邹小农.中国12市县1993年~1997年肿瘤发病和死亡登记资料统计分析[J].中国肿瘤,2002,11(9):497-507. 被引量:193
  • 2Hamilton S R, Vogelstein B, Kudo S, et al. Carcinoma of the colon and reetum[M]. //Hamilton S R, Aaltonen, L A. World health organization classification of turnouts, pathology and ge netics of tumours ofthe digestive system. Lyon: IARC Press, 2000:105-119.
  • 3Minhajat R, Mori D, Yamasaki F, et al. Endoglin(CD105)expression in angiogenesis of colon cancer: analysis using tissue mi croarrays and comparison with other endothelial markers[J]. Virchows Arch, 2006,448(2):127-134.
  • 4Risau W. Angiogenic growth factors[J]. Prog Growth Factor Res, 1990,2(1) :71-79.
  • 5Neufeld G, Tessler S, Gitay-Goren H, et al. Vascular endothe lial growth factor and its receptors[J]. Prog Growth Factor Res, 1994, 5(1):89-97.
  • 6Mesri M, Morales Ruiz M, Ackermann E J, et al. Suppression of vascular endothelial growth factor-mediated endothelial cell protection by survivin targeting[J]. Am J Pathol,2001,158(5) : 1757-1765.
  • 7Shimizu M, Saitoh Y, Itoh H. Immunohistochemical staining of Ha-ras oncogene product in normal, benign, and malignant human pancreatic tissues[J]. Hum Pathol,1990,21(6):607-612.
  • 8Conway E M, pollefreyt S, Comelissen J, et al. Three differentially expressed survivin cDNA variants encode proteins with distinct antiapoptotic functions[J]. Blood, 2000, 95(4) : 1435-1442.
  • 9Kawasaki H, Toyoda M, Shinohara H, et al. Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis [J]. Cancer, 2001, 91 (11) : 2026-2032.
  • 10王滔明,许建明,胡乃中.Survivin、COX-2和VEGF在胃癌中的表达及其与预后的意义[J].临床消化病杂志,2007,19(1):35-39. 被引量:8

二级参考文献24

  • 1Saad R S, Jasnosz K M, Tung M Y, et al. Endoglin (CD105) expression in endometrial carcinoma[J].Int J Gynecol Pathol,2003,22(3):248-253.
  • 2Dales J P, Garcia S, Bonnier P, et al. CD105 expression is a marker of high metastatic risk and poor outcome in breast carcinomas. Correlations between immunohistochemical analysis and long-term follow-up in a series of 929 patients[J]. Am J Clin Pathol,2003,119(3):374-380.
  • 3Wikstrom P, Lissbrant I F, Stattin P, et al. Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer[J].Prostate,2002,51(4):268-275.
  • 4Duff S E, Li C, Garland J M, et al. CD105 is important for angiogenesis: evidence and potential applications[J].FASEB J,2003,17(9):984-992.
  • 5Yagasaki H, Kawata N, Takimoto Y, et al. Histopathological analysis of angiogenic factors in renal cell carcinoma[J].Int J Urol,2003,10(4):220-227.
  • 6Nakai S, Masaki T, Shiratori Y, et al. Expression of p57(KIP2) in hepatocellular carcinoma: relationship between tumor differentiation and patient survival[J]. Int J Oncol. 2002,20(4):769-775.
  • 7Fonsatti E,Del Vecchio L,Altomonte M,et al. Endoglin: An accessory component of the TGF-beta-binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies[J]. J Cell Physiol,2001,188(1):1-7.
  • 8Neufeld G, Cohen T,Gengrinovitch S, et al. Vascular endothelial growth factor (VEGF) and its receptors[J]. FASEB J,1999,13(1):9-22.
  • 9Hirohashi S, Ishiak K G,Kojiro M, et al. Hepatocellular carcinoma[A]. Hamilton S R, Aaltonen L A. World health organization classification of tumours. Pathology and genetics of tumours of the digestive system[C]. Lyon: IARC Press,2000.159-172.
  • 10Ito Y, Takeda T, Sasaki Y, et al. Expression of p57/Kip2 protein in extrahepatic bile duct carcinoma and intrahepatic cholangiocellular carcinoma[J]. Liver, 2002,22(2):145-149.

共引文献209

同被引文献53

引证文献4

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部